Certificate PL-26-00317 · Tesofensine 500 mcg Capsules (30 ct) · lot PL-2610-204
VerifyCertificate page
PrymaLab
PrymaLab
PrymaLab Analytical · In-house laboratory
3705 Music Branch Rd, Ashland, KY 41102 · +1 (606) 465-9063 · prymalab.net
Certificate no.
PL-26-00317
Verification key
ERXVXMDU
Scan or enter both at
prymalab.net/testing/verify

Certificate of Analysis · Lot release

Tesofensine 500 mcg Capsules (30 ct)

Lot PL-2610-204 · Capsules · Label claim 500 mcg per capsule
Tested in-house by PrymaLab
In-house analytical result,
not an independent third-party test
Lot / batch number
PL-2610-204
Date made
2026-10-07
Date of analysis
2026-10-09
Date issued
2026-10-15
Retest / expiry
2028-10-07
Units in lot / sampled
239 / 2
Storage
—
Certificate type
Lot COA, 2 pages
Compound
Tesofensine
Tesofensine (NS-2330), phenyltropane; small molecule
CAS number
195875-84-4
Molecular formula
C17H23Cl2NO
Theoretical mass (avg.)
328.28 Da
Structure
Purity · RP-HPLC, area %
99.61%
Specification ≥ 99.0% • main peak at 8.38 min
Identity · Observed Mass
328.26 Da
Theoretical 328.28 Da • −0.02 Da (61 ppm)
Overall conclusion
PASS
Meets every specification for the tests performed
TestMethodSpecificationResultConclusion
Identity (mass)LC-MS, ESI positiveTheoretical ± 1.0 Da328.26 DaPASS
PurityRP-HPLC, UV 254–306 nm, area%≥ 99.0%99.61%PASS
Largest impurityRP-HPLC, area%≤ 1.0%0.19% (RT 9.90)PASS
Capsule contentContent vs label claim0.45–0.55 mg/cap0.50 mg/capPASS
Bacterial endotoxinLAL, kinetic——N/A
Aerobic count (TAMC)USP <61>< 10 CFU/g< 10 CFU/gPASS
Yeast & mold (TYMC)USP <61>< 10 CFU/g< 10 CFU/gPASS
E. coliUSP <62>AbsentAbsentPASS

1HPLC chromatogram

Data file: PL-2610-204-HPLC.raw · Column C18, 150 × 4.6 mm · UV 254–306 nm
0.01%0.1%1%10%100%67891011Retention time (min) · stick height = area % (log scale)99.61% · 8.38 min0.12% †0.08% †0.19% †
Peak plot drawn from the integrated peak table (area %, log scale); it is not the instrument trace, which is retained in PL-2610-204-HPLC.raw. † Nominal reference retention time for the assigned impurity; the main-peak RT is observed in this lot.
PrymaLab
PrymaLab
Certificate of Analysis · continued
Tesofensine 500 mcg Capsules (30 ct) · Lot PL-2610-204 · Certificate PL-26-00317
Lot PL-2610-204
Method, peak table and approval

2HPLC method · PL-2610-204-HPLC.raw

Instrument
Waters Alliance e2695
Data System
Empower 3
Detector
UV absorbance
Detection Wavelength
254–306 nm
Column
C18, 150 × 4.6 mm, 3.5 µm
Mobile Phase A
0.1% TFA in water
Mobile Phase B
0.1% TFA in MeCN
Gradient
5–95% B over 25 min (linear)
Flow Rate
1.0 mL/min
Column Temperature
40 °C
Injection Volume
10 µL

3Gradient program

Time (min)% A% B
0.0955
25.0595

4Peak table

PeakRT (min)AreaArea %
17.40 †—0.12
28.38—99.61
39.20 †—0.08
49.90 †—0.19
Total—100.00
Peaks: 1 unidentified impurity; 2 main peak (Tesofensine); 3 unidentified impurity; 4 unidentified impurity · Area % from the integrated peak table (absolute areas are not part of the lot-release export) · † nominal reference RT for the assigned impurity · Purity = main peak area ÷ total integrated area × 100, to two decimals; main peak shaded.

5Identity by mass spectrometry

Instrument
Waters SQD
Ionization / Mode
ESI, positive
Reference m/z (ion)
329.29 [M+H]+
Deconvoluted Mass
328.26 Da
Theoretical Mass
328.28 Da
Difference
−0.02 Da (61 ppm)
Data File
PL-2610-204-MS.d
Acceptance
Within ± 1.0 Da

6Additional tests

TestPerformed byDateReport / file
Content vs label claimPrymaLab Analytical2026-10-09—
Microbial limits (USP <61>/<62>)PrymaLab Analytical2026-10-15—
A test with no row here was not performed on this lot. Outside-laboratory reports, when used, are attached and named below.

7Review and approval

D. Reynolds
Analyst · performed the testing
Date: 2026-10-15
S. Calloway
Reviewer · checked against raw data
Date: 2026-10-15
M. Phelps
Lab Director · approved for release
Date: 2026-10-15